White Paper

Pharma's Frozen Assets

GettyImages-1070962894 pharmacy

Years after the COVID-19 outbreak, the medical industry is still battling the logistical challenges of delivering vaccines globally. This is mostly related to the scaling up of the refrigerated networks that make up part of the global “cold chain” — the uninterrupted process of maintaining end-to-end temperature-controlled conditions from the manufacturing site to the point of care.

Unlike ambient temperature medicines, cold chain drugs require more energy and care to ensure a successful delivery that doesn’t spoil the product. If pharmaceutical companies want to live up to their ambitious environmental, social, and governance (ESG) targets, they will need to understand current and future trends and work closely with logistics companies to ensure delivery of often live-saving cold chain medicines whilst having their CO2 footprint in mind.

Delve into a data-driven approach to assess the volume and value of cold chain medicines by combining IQVIA audit data with publicly available data.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader